logo-loader
viewVolitionRx

VolitionRx reports strong second quarter as it moves forward on key MoUs

VolitionRx Limited's (NYSEAMERICAN:VNRX) Cameron Reynolds caught up with Proactive London's Andrew Scott to discuss the group's second quarter update.

Reynolds says they've continued to strengthen the balance sheet with cash and cash equivalents increasing significantly thanks to warrant exercises by investors.

He adds they're now looking to advance the previously announced large-scale colorectal cancer trials in Europe, the US and Asia as well as the clinical trial program for lung cancer.

Quick facts: VolitionRx

Price: 4.28 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $175.88 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

VolitionRx CEO discusses 'spectacular' results from Nu.Q proof of concept study

VolitionRx Limited's (NYSEAMERICAN:VNRX) Cameron Reynolds discusses with Proactive London's Andrew Scott the results from the latest proof of concept study on its Nu.Q cancer-test assay. He says the finding's have revealed an impressive ability to detect with accuracy non-Hodgkins lymphoma...

1 day, 12 hours ago

2 min read